Animal drug manufacturer VIC-Pharma, a new resident of the Technopolis Moscow special economic zone (SEZ), will launch a 2.1-billion-ruble ($23.8 million) veterinary pharmaceuticals production facility at the site in 2026, according to Maxim Liksutov, Moscow’s deputy mayor for transport and industry.
“Another resident of Technopolis Moscow is a company specializing in the development and manufacture of drugs for animals,” Liksutov was quoted as saying on the mos.ru portal. “A production facility spanning nearly 5,3 thousand square meters will open at the Alabushevo site. For the implementation of the project, with an investment of over 2.1 billion rubles, the resident will create more than 100 jobs.”
The product range is planned to include at least 15 drugs for treating infectious diseases in poultry – coccidiosis and necrotic enteritis. The main customers for this product are large agricultural holdings in Russia and CIS countries. The launch of production is scheduled for the third quarter of next year.
According to the statement, VIC-Pharma intends to establish an R&D center for drug research and development within the economic zone and significantly expand its product line by increasing production capacity.